Navanshu Arora
Expertise in
39
conditions

Dr. Navanshu Arora

Hematology | Oncology
Valley Professional Center North 3915 Talbot Rd S, Ste 300, 
Renton, WA 
Accepting New Patients
Offers Telehealth
Expertise in
39
conditions
Valley Professional Center North 3915 Talbot Rd S, Ste 300, 
Renton, WA 

Overview

Navanshu Arora, MD, is a University of Missouri-Kansas City fellowship-trained physician specializing in Hematology & Oncology. He offers expeditious consultation and comprehensive evaluation and treatment for all cancer-related conditions. In 2008, Dr. Arora received an award for “Top 10 Doctors” which recognizes patient satisfaction. He has contributed to more than 20 publications and actively pursued teaching students and residents in the University of Missouri School of Medicine. Dr. Arora held the position of docent for UMKC students and won the outstanding docent award. He was also elected as a Fellow for the American College of Physicians. He did enroll the highest number of patients through the cooperative group trials for two years running. He also has been a principal investigator in a breast cancer trial.

Dr. Arora is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Angiosarcoma, Inflammatory Breast Cancer, Familial Colorectal Cancer, Colorectal Cancer, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 3 clinical trials. Dr. Arora is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in WA

Hospital Affiliations

Valley Medical Center
Valley Medical Group Provider

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Oncology & Hematology Clinic
Valley Professional Center North 3915 Talbot Rd S, Ste 300, Renton, WA 98055

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)
A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)
Enrollment Status: Terminated
Publish Date: June 17, 2026
Intervention Type: Drug
Study Drugs: Canakinumab, Pembrolizumab, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed
Study Phase: Phase 3
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Canakinumab
Study Phase: Phase 3
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole, Goserelin, Leuprolide
Study Phase: Phase 3
View 2 Less Clinical Trials

1 Total Publications

Spontaneous regression of hepatocellular cancer: case report and review of literature.
Spontaneous regression of hepatocellular cancer: case report and review of literature.
Journal: Gastrointestinal cancer research : GCR
Published: February 28, 2012
Similar Doctors
Expertise in
22
conditions
Dr. Douglas S. Hawkins
Hematology | Oncology
Expertise in
22
conditions
Dr. Douglas S. Hawkins
Hematology | Oncology
Referral may be required

Seattle Children's Hospital

4800 Sand Point Way NE, 
Seattle, WA 
 (15.4 miles away)
206-987-2000
Languages Spoken:
English, German
See accepted insurances
Accepting New Patients
Offers Telehealth

Douglas Hawkins is a Hematologist and an Oncologist practicing medicine in Seattle, Washington. Dr. Hawkins is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Rhabdomyosarcoma, Adult Soft Tissue Sarcoma, Osteosarcoma, Osteotomy, and Bone Marrow Aspiration. Dr. Hawkins is currently accepting new patients.

Expertise in
24
conditions
Dr. Sarah S. Leary
Hematology | Oncology
Expertise in
24
conditions
Dr. Sarah S. Leary
Hematology | Oncology
Referral may be required

Seattle Children's Hospital

4800 Sand Point Way NE, 
Seattle, WA 
 (15.4 miles away)
206-987-2106
Languages Spoken:
English, Castilian, French, Hindi, Mandarin, Punjabi, Spanish, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Sarah Leary is a Hematologist and an Oncologist practicing medicine in Seattle, Washington. Dr. Leary is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Medulloblastoma, Glioma, Gliomatosis Cerebri, Brain Tumor, and Bone Marrow Aspiration. Dr. Leary is currently accepting new patients.

Expertise in
11
conditions
Dr. James M. Olson
Hematology | Oncology
Expertise in
11
conditions
Dr. James M. Olson
Hematology | Oncology
Referral may be required

Seattle Children's Hospital

4800 Sand Point Way NE, 
Seattle, WA 
 (15.4 miles away)
206-987-2106
Languages Spoken:
English, Afrikaans, Korean, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

James Olson is a Hematologist and an Oncologist practicing medicine in Seattle, Washington. Dr. Olson is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Posterior Fossa Tumor, and Glioma. Dr. Olson is currently accepting new patients.

Frequently Asked Questions about Dr. Navanshu Arora

How do I make an appointment with Dr. Navanshu Arora?

You can book an appointment with Dr. Navanshu Arora by calling their office at 425-690-3409. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Navanshu Arora a top-rated expert for Angiosarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Navanshu Arora is classified as an Distinguished expert for Angiosarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Navanshu Arora specialize in?

While Dr. Navanshu Arora is a Hematology, they have specific expertise in Angiosarcoma, Inflammatory Breast Cancer, and Familial Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Navanshu Arora participate in research or clinical trials?

Yes. Dr. Navanshu Arora has published 1 articles and abstracts on conditions like Angiosarcoma. You can view a list of Dr. Navanshu Arora's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Navanshu Arora accept my insurance?

Dr. Navanshu Arora accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 425-690-3409 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Arora's expertise for a condition
ConditionClose
    View All 34 Advanced Conditions
    View All 115 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile